Bile formation in long-term ex situ perfused livers

Long-term ex situ liver perfusion has emerged as a potential method to evaluate and possibly restore injured liver grafts before transplantation. However, the dynamics of bile formation during such perfusion remain poorly understood. Prior research has shown that bile flow can reflect liver viability, but its role in extended perfusion settings is unclear. No prior work had resolved how bile flow changes over time in ex situ systems. This gap motivated a closer examination of bile flow stimulation and its implications for liver function. It was already known that bile flow is influenced by various pharmacological agents, but their specific effects in long-term perfusion were not fully characterized. The uncertainty around bile flow as a viability marker in extended perfusion systems created a need for controlled experimental protocols. This study aimed to address these gaps by developing a bile stimulation protocol and analyzing its effects. The lack of standardized methods for bile flow assessment in ex situ systems further highlighted the need for this research.

The study aimed to develop and validate a bile stimulation protocol during long-term ex situ liver perfusion. The specific problem addressed was the lack of understanding about how bile flow behaves in extended perfusion and whether it can serve as a reliable viability marker. The motivation stemmed from the need to improve the assessment of liver graft function before transplantation. By establishing a protocol for bile stimulation, the researchers sought to determine if bile flow could be maintained or restored in perfused livers. The study also aimed to compare the effects of different bile stimulators, such as taurocholic acid and ursodeoxycholic acid. The researchers wanted to evaluate whether continuous administration of these agents could maintain bile flow over time. The goal was to determine if bile flow could be stimulated independently of bile salt concentration. This work aimed to provide a framework for assessing liver viability through bile flow during ex situ perfusion.

The study used porcine and human livers perfused under near-physiologic conditions to develop and test a bile stimulation protocol. In phase 1, porcine livers were perfused with blood and treated with taurocholic acid to stimulate bile flow. The administration of piperacillin-tazobactam and methylprednisolone was modified from daily boluses to continuous infusion. In phase 2, the protocol was adapted for human livers, replacing taurocholic acid with medical-grade ursodeoxycholic acid. Bile flow was measured over time to assess the effects of each stimulator. The researchers monitored changes in bile flow and its components to determine the impact of the drugs. They also observed the effects of bolus administration of tazobac/methylprednisolone on bile flow recovery. The study compared the outcomes of livers that maintained continuous bile flow with those that did not. The methods focused on evaluating the efficacy of different bile stimulation strategies in ex situ systems.

Phase 1 results showed that taurocholic acid stimulated bile flow in porcine livers. The addition of tazobac and methylprednisolone shifted from bolus to continuous application improved bile flow stability. In phase 2, human livers initially showed a decline in bile flow from 29.3 ± 6.5 to 9.3 ± 1.4 mL/h after taurocholic acid administration. However, a bolus of tazobac/methylprednisolone increased bile flow to 39.0 ± 9.7 mL/h, with a decrease in solid bile components. This suggested that tazobac/methylprednisolone stimulated bile flow independently of bile salt concentration. In phase 2, ursodeoxycholic acid replaced taurocholic acid and successfully stimulated bile flow in human livers. Eight livers maintained continuous bile flow for 1 week. Four livers showed progressive cell death, with only one exhibiting bile flow. These findings indicated that the presence of bile flow alone is not sufficient to assess liver viability.

The study demonstrated that bile flow can be stimulated during long-term ex situ liver perfusion using specific agents. The authors concluded that tazobac/methylprednisolone can induce bile flow independently of bile salt concentration. They also found that medical-grade ursodeoxycholic acid is a suitable replacement for nonmedical-grade taurocholic acid. The results suggest that bile flow stimulation is possible even when bile salt levels decline. However, the authors emphasized that the presence of bile flow alone is not sufficient to determine liver viability. The study showed that some livers with low or absent bile flow still exhibited signs of deterioration. The findings imply that bile flow stimulation must be combined with other viability markers for accurate assessment. The authors propose that proper administration of stimulators can maintain bile flow during extended perfusion.